3 Tried and True Dividend Stocks to Buy for Your Portfolio
Picking income stocks can be challenging. Some companies pay dividends only to cut them in the future, and others are more focused on stock buybacks instead of dividends.
Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance
Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.
Best Dow Jones Stocks To Buy Right Now? 2 For Your Watch List
Check out these Dow Jones stocks for your May 2024 watch list.
Dr. Gottlieb on Amgen's new weight loss drug: Expect to be on par with Wegovy & Mounjaro or better
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss Amgen's new injectable weight loss drugs, how it takes a different approach from other weight loss drugs like Wegovy and Mou...
Amgen Could Become A Real Contender In The Obesity Market
Amgen's shares surged after management's earnings call comments about the phase 2 trial of obesity candidate MariTide. These comments and previous phase 2 data point to the increasing possibility o...
Why Amgen Stock Zoomed Nearly 12% Higher Today
The pharmaceutical sector mainstay published its first-quarter results. These beat on both the top and bottom lines.
Amgen (AMGN) Q1 Earnings Top, Stock Up on Obesity Drug Update
Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.
Amgen (AMGN) Sales Higher After Obesity Drug Results
Amgen (AMGN) sales are higher after early results from a study of an obesity drug. Renita Young discusses this as the Amgen CEO is “very encouraged” by the results of the obesity drug study.
Amgen shares soar on obesity drug optimism
Amgen Inc (NASDAQ:AMGN, ETR:AMG) shares gained almost 13% at about $314 in early trade on Friday after the drugmaker said it was “very encouraged” by interim trial data for its experimental weight ...
Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data
Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on it...
Amgen shares jump after teasing 'encouraging' weight loss data
U.S. drugmaker Amgen's shares jumped 13% to $316.26 premarket on Friday as the company teased encouraging data for its experimental obesity drug, igniting investor hopes but leaving Wall Street fru...
Amgen Stock Jumps on Obesity Drug Optimism. What Comes Next.
The company is trying to carve a niche in a rapidly growing obesity-drug market that's currently dominated by Eli Lilly and Novo Nordisk.
Amgen Stock Surges After Q1 Earnings Beat, 'Encouraging' Weight-Loss Drug Update
Amgen (AMGN) shares surged more than 14% in extended-hours trading on Thursday after the biopharmaceutical giant posted quarterly earnings that came in ahead of Wall Street expectations and provide...
Amgen, Inc. (AMGN) Q1 2024 Earnings Call Transcript
Amgen, Inc. (NASDAQ:AMGN ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President James Bradner - EVP, Resear...
Here's What Key Metrics Tell Us About Amgen (AMGN) Q1 Earnings
The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimat...
Related Companies